Paras Healthcare

Paras Healthcare Limited was founded in 1987 with a vision to bridge the critical healthcare infrastructure gap in underserved regions of India. Over nearly four decades of operations, the company has scaled its footprint significantly, emerging as the fifth-largest healthcare provider across North India, Bihar, and Jharkhand. From its early origins, the company has continuously evolved, crossing key infrastructure milestones such as expanding its bed capacity from 1,250 beds in March 2022 to 2,135 beds by March 2024, supported by a dedicated professional workforce of over 1,091 doctors and 1,509 nurses.

The core business model centers around operating multi-specialty hospitals under the Paras Health brand, focusing heavily on tier 2 and tier 3 cities where specialized medical infrastructure is historically deficient. The company's specialized clinical portfolio covers advanced tertiary care verticals including heart care, cancer treatment, brain and nerve care, digestive health, and bone and joint replacement services. By deploying state-of-the-art diagnostic and therapeutic medical technologies, Paras Health ensures that complex clinical procedures are made accessible to populations outside major metropolitan hubs.

The target market comprises vast demographic clusters across North India, Bihar, Jharkhand, Haryana, Punjab, Rajasthan, Uttar Pradesh, and Jammu and Kashmir. The institutional customer base benefits from empaneled government health schemes, third-party administrators (TPAs), and corporate tie-ups, ensuring steady patient inflows and high operational stickiness. The hospital network maintains rigorous quality accreditations and clinical standards, which foster deep brand trust and high patient retention across its regional hubs located in cities like Gurugram, Patna, Udaipur, Ranchi, and Srinagar.

Operationally, the company demonstrates high efficiency in asset utilization and clinical staffing, maintaining a strong nurse-to-bed ratio of 1.29 as of Q1 FY2027. Its manufacturing and infrastructural capabilities encompass advanced modular operation theatres, intensive care units (ICUs), and advanced oncology and cardiology suites. While extensive clinical R&D is decentralized, the group continuously invests in upgrading medical equipment, adopting digital health records, and implementing transaction management systems to streamline patient care workflows.

Promoted by experienced healthcare entrepreneurs and managed by a seasoned institutional leadership team, Paras Healthcare is strategically positioned for regional consolidation and greenfield expansion. The promoter group maintains a balanced governance structure aligned with international operational standards. Strategic expansion initiatives focus on deepening penetration within its core geographies while exploring synergistic opportunities in adjacent tier 2 markets to capture rising domestic healthcare expenditures.

The Paras Healthcare Limited initial public offering is structured as a book-built issue aggregating approximately ₹1,450 crores. The issue comprises a fresh issue of approximately ₹500 crores and an offer for sale (OFS) of approximately ₹950 crores. The price band is set between ₹660.0 and ₹693.0 per equity share with a face value of ₹1 per share. The issue is slated to open on October 21, 2026, and close on October 23, 2026, with listing proposed on both BSE and NSE following allotment finalization on October 26, 2026.

The net proceeds from the fresh issue component of ₹500 crores are targeted toward funding strategic growth initiatives, including capital expenditure for setting up new hospitals, repayment or pre-payment of certain borrowings availed by the company, and general corporate purposes. The substantial OFS component of ₹950 crores indicates partial monetization by existing institutional investors and promoters, which reduces the net primary capital infusion directly flowing into the company's balance sheet.

From a financial performance perspective, the company has experienced a turnaround, transitioning from a basic EPS of -₹5.94 in Fiscal 2025 to a positive basic EPS of ₹4.34 in Fiscal 2026. Historical revenues have expanded steadily in tandem with operational bed additions and increasing Average Revenue Per Occupied Bed (ARPOB). EBITDA margins have shown progressive improvement due to better bed occupancy rates and operational maturity across newer hospital units, though historical return metrics like ROE and ROCE reflect capital-intensive gestation phases typical of hospital networks.

In terms of valuation and peer benchmarking, Paras Healthcare trades at earnings multiples comparable to mid-tier listed hospital peers such as Yatharth Hospital and Jupiter Hospitals, while remaining at a discount to established large-cap leaders like Apollo Hospitals and Max Healthcare. The face value is ₹1 per share. With a basic EPS of ₹4.34 for Fiscal 2026, the valuation demands careful scrutiny regarding the timeline required for mature units to fully offset the depreciation and interest drag of newer facilities.

Key investment highlights include the company's strong regional moat in underserved tier 2 and tier 3 markets of North and East India, favorable long-term macroeconomic tailwinds favoring organized healthcare, and a professionalized clinical setup. However, investor participation has been notably muted, with total subscription closing at a modest 0.23x, driven by low QIB demand at 0.06x and retail subscription at 0.8x, signaling conservative institutional appetite.

Principal risk factors include high capital intensity, gestation lags in greenfield hospital projects, regulatory pricing pressures on healthcare services, and potential execution risks in managing multi-unit geographical expansions. Furthermore, the low subscription pacing and a modest grey market premium of ₹14.0 (representing a 2.02% gain expectation over the price band) highlight near-term listing caution among market participants.